
This amount of restricted cash will reduce over time and return to the cash and cash equivalents line on the balance sheet. This includes approximately $36 million of restricted cash related to a guarantee for rights.


This represents a 99% year-over-year improvement, driven primarily by a reduction in stock-based compensation compared to the second quarter ended June 30, 2021. Group Net Loss: Group net loss was $4.8 million in the quarter.Sports Technology & Services: Revenue grew 57% (75% on a constant currency basis) year-over-year to $11.3 million, primarily driven by the inclusion of revenues derived from Second Spectrum, as well as expanded services provided to existing sports league and federation customers across all tiers of sport.Media Technology, Content & Services: Revenue increased 88% (109% on a constant currency basis) year-over-year to $15.0 million, predominately organic growth driven by increasing uptake of programmatic advertising services.Betting Technology, Content & Services: Revenue increased 10% (23% on a constant currency basis) year-over-year to $44.8 million, driven by increased utilization of available content, expansion of value-add services and new service offerings, and new customer acquisitions.On a constant currency basis, revenue increased $21.0 million, or 42% year-over-year. Group Revenue: Group revenue increased 27% year-over-year to $71.1 million.Overall, results provide evidence of alterations in expression of innate immune genes prior to onset of T1D.

Another gene within the module, CAMP, is potentially relevant based on its role in promoting β-cell survival in a murine model. The hub gene, LTF, is known to have immunomodulatory properties.

We identified a module of 14 coexpressed genes with roles in the innate immunity. Gene Ontology pathway analysis of the top 150 differentially expressed genes (nominal P < 0.01) identified significantly enriched pathways including leukocyte activation involved in immune response, innate immune response, and regulation of immune response. Weighted gene coexpression network analysis was used to identify coexpression modules. With linear mixed models we tested for changes in expression after IA that differed across individuals who progressed to T1D (progressors) ( n = 25), reverted to an autoantibody-negative stage (reverters) ( n = 47), or maintained IA positivity but did not develop T1D (maintainers) ( n = 66). Illumina’s NovaSeq 6000 was used to quantify gene expression in whole blood. We identified individuals from Diabetes Autoimmunity Study in the Young (DAISY) who developed IA, autoantibodies present on two or more visits. Longitudinal changes in gene expression during islet autoimmunity (IA) may provide insight into biological processes that explain progression to type 1 diabetes (T1D).
